Published in Anticancer Drugs on March 01, 2006
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma | NCT01391962
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med (2007) 2.90
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos (2008) 1.46
Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs (2010) 1.25
Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs (2010) 1.21
Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res (2011) 1.10
Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. Int J Clin Oncol (2009) 1.03
Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice. BMC Pharmacol (2010) 0.94
Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol (2011) 0.93
Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.93
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer (2008) 0.92
Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Cancer Chemother Pharmacol (2011) 0.89
Marginal increase of sunitinib exposure by grapefruit juice. Cancer Chemother Pharmacol (2010) 0.89
Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol (2013) 0.83
Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. Br J Clin Pharmacol (2015) 0.78
Potential protective effect of sunitinib after administration of diclofenac: biochemical and histopathological drug-drug interaction assessment in a mouse model. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.78
Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor. Clin Pharmacokinet (2016) 0.76
Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021. Cancer Med (2016) 0.75
Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker. CPT Pharmacometrics Syst Pharmacol (2016) 0.75
Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives. Onco Targets Ther (2016) 0.75
Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence. Clin Pharmacokinet (2015) 0.75
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med (2007) 2.90
Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol (2010) 2.68
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res (2010) 1.71
Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood-loss non-cardiac surgery: results of a European phase 3 study. Anesthesiology (2002) 1.64
A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol (2012) 1.61
Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. Blood (2012) 1.31
Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn (2011) 1.06
Clinical pharmacology of axitinib. Clin Pharmacokinet (2013) 1.02
Non-compartment model to compartment model pharmacokinetics transformation meta-analysis--a multivariate nonlinear mixed model. BMC Syst Biol (2010) 1.00
A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Invest New Drugs (2012) 0.98
Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers. Cancer Chemother Pharmacol (2012) 0.96
Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. Cancer Chemother Pharmacol (2010) 0.95
Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study). Invest Ophthalmol Vis Sci (2012) 0.94
Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine. PLoS One (2013) 0.92
Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). Ophthalmology (2012) 0.89
Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemother Pharmacol (2009) 0.89
Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. Invest New Drugs (2010) 0.89
Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial. Ophthalmology (2012) 0.87
Dose response with onabotulinumtoxinA for post-stroke spasticity: a pooled data analysis. Mov Disord (2010) 0.85
EBF recommendation on the validation of bioanalytical methods for dried blood spots. Bioanalysis (2011) 0.85
An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. Breast (2012) 0.84
Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB. Int Urogynecol J (2012) 0.82
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 - LBA and immunogenicity). Bioanalysis (2014) 0.80
Assay formats: Recommendation for best practices and harmonization from the global bioanalysis consortium harmonization team. AAPS J (2013) 0.80
Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. Breast (2012) 0.79
EBF and dried blood spots: from recommendations to potential resolution. Bioanalysis (2011) 0.78
Connecting strategies on dried blood spots. Bioanalysis (2010) 0.77
Conference report: Discussion on harmonization and globalization of bioanalytical guidances at the 19th International Reid Bioanalytical Forum. Bioanalysis (2011) 0.76
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 - hybrid LBA/LCMS, ELN & regulatory agencies' input). Bioanalysis (2014) 0.76
Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans. Drug Metab Dispos (2014) 0.75
Feedback from the European Bioanalysis Forum Workshop: taking tiered approach to the next level. Bioanalysis (2014) 0.75
Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy. J Cardiovasc Med (Hagerstown) (2017) 0.75
Managing scientific, technical and regulatory innovation in regulated bioanalysis: a discussion paper from the European Bioanalysis Forum. Bioanalysis (2013) 0.75
Updates from the EBF DBS--microsampling consortium. Bioanalysis (2012) 0.75
Conference Report: the 3rd EBF Focus Meeting: 'Hatching'--emerging technologies approaching the regulated bioanalysis laboratory. Brussels, Belgium, 12-13 June 2012. Bioanalysis (2012) 0.75
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 1--small molecules by LCMS). Bioanalysis (2014) 0.75
Integrating disease progression models, non-clinical pharmacokinetic data and treatment response endpoints to optimize intravitreal dosing regimens. Int J Clin Pharmacol Ther (2014) 0.75
Radiation torque on a spherical birefringent particle in the long wave length limit: analytical calculation. Opt Express (2005) 0.75
From challenges to solutions. European Bioanalysis Forum 3rd Annual Open Symposium, Hesperia Towers, Barcelona, Spain, 1-3 December 2010. Bioanalysis (2011) 0.75